NasdaqCM - Nasdaq Real Time Price USD

CalciMedica, Inc. (CALC)

Compare
4.2800 -0.2400 (-5.31%)
As of 1:32 PM EDT. Market Open.
Loading Chart for CALC
DELL
  • Previous Close 4.5200
  • Open 4.3300
  • Bid --
  • Ask 4.3000 x 100
  • Day's Range 3.9707 - 4.4101
  • 52 Week Range 1.7500 - 8.3800
  • Volume 26,844
  • Avg. Volume 41,807
  • Market Cap (intraday) 46.011M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1700
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.33

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

www.calcimedica.com

13

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CALC

View More

Performance Overview: CALC

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CALC
49.65%
S&P 500
20.29%

1-Year Return

CALC
59.11%
S&P 500
34.26%

3-Year Return

CALC
10.46%
S&P 500
31.22%

5-Year Return

CALC
10.46%
S&P 500
31.22%

Compare To: CALC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CALC

View More

Valuation Measures

Annual
As of 9/26/2024
  • Market Cap

    46.33M

  • Enterprise Value

    7.41M

  • Trailing P/E

    0.31

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.35

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -64.92%

  • Return on Equity (ttm)

    -83.76%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -12.59M

  • Diluted EPS (ttm)

    -0.1700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.14M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -12.45M

Research Analysis: CALC

View More

Company Insights: CALC

Research Reports: CALC

View More

People Also Watch